EUVIMEDEUVIMED entdecken
Vergleichsstudie

MAFLD predicts cardiovascular disease risk better than MASLD

Ziyan Pan, Gamal Shiha iD, Gamal Esmat, Nahum Méndez-Sánchez iD, Mohammed Eslam iD

Liver International · 2024

DOI: 10.1111/liv.15931 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Liver International, 2024. Verfasst von Ziyan Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Nutrition Surveys, Cardiovascular Diseases. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Health and Medical Research Council of Australia (NHMRC) Program Grant, Project and ideas grants, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).

Methods

Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed.

Results

MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone.

Conclusions

Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nutrition SurveysCardiovascular DiseasesHumansMaleFemaleMiddle AgedRisk AssessmentAdultRisk FactorsUnited StatesAgedNon-alcoholic Fatty Liver DiseaseLogistic ModelsHeart Disease Risk Factors

Autor:innen und Institutionen

  • Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia.
  • Gastroenterology and Hepatology Department, Egyptian Liver Research Institute and Hospital, Mansoura, Egypt.
  • Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Departement of Endemic Medicine and Hepatogastrenterology, Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Gastroenterology and Hepatology Department, Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.

ORCID-Profile: Gamal Shiha, Nahum Méndez-Sánchez, Mohammed Eslam

Förderung

  • National Health and Medical Research Council of Australia (NHMRC) Program Grant
  • Project and ideas grants
  • National Health and Medical Research Council

Zitieren

APA

Pan, Z., Shiha, G., Esmat, G., Méndez-Sánchez, N., & Eslam, M. (2024). MAFLD predicts cardiovascular disease risk better than MASLD. Liver International. https://doi.org/10.1111/liv.15931

Vancouver

Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver International. 2024. doi:10.1111/liv.15931

BibTeX
@article{Pan2024,
  author = {Pan, Ziyan and Shiha, Gamal and Esmat, Gamal and Méndez-Sánchez, Nahum and Eslam, Mohammed},
  title = {MAFLD predicts cardiovascular disease risk better than MASLD},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15931}
}
Kostenlos starten →